Table 5. KF41399 effects on antitumor... | American Society of Hematology

Table 5.

KF41399 effects on antitumor activity of ACNU against human lung carcinoma LC-6 inoculated into nude mice

Group	Dose (mg/kg)	Schedule (day)	T/C^5-150 (%)	Body weight^5-151 (g)	Mortality	Platelet counts (×10⁴/μL^5-152)
Control			100	−0.7	0/5	102.9 ± 8.9
KF41399	25 (PO)	0-1	96	−1.2	0/5	124.9 ± 10.7
ACNU	45 (IV)	2-3	0	−4.5	1/5	41.2 ± 16.0^5-153
KF41399 + ACNU	25 (PO)	0-1
	45 (IV)	2-3	0	−2.2	0/5	78.6 ± 11.0^5-153

Group	Dose (mg/kg)	Schedule (day)	T/C^5-150 (%)	Body weight^5-151 (g)	Mortality	Platelet counts (×10⁴/μL^5-152)
Control			100	−0.7	0/5	102.9 ± 8.9
KF41399	25 (PO)	0-1	96	−1.2	0/5	124.9 ± 10.7
ACNU	45 (IV)	2-3	0	−4.5	1/5	41.2 ± 16.0^5-153
KF41399 + ACNU	25 (PO)	0-1
	45 (IV)	2-3	0	−2.2	0/5	78.6 ± 11.0^5-153

PO, oral; IV, intravenous.

LC-6 cells (8-mm³ fragment) were inoculated into BALB/c nu/nu mice. When tumors grew to a size between 50 and 300 mm³, therapy was initiated.

Minimum T/C;

maximum body weight change;

platelet counts on day 10;

P < .05.